Stocks
35950NQI
YHDHealthcareBiotechnology
A clinical-stage biopharmaceutical company developing precision therapies for genetically defined cancers and rare diseases. Its lead programs target specific genetic mutations in oncology, with early-stage trials underway. Investors track the company for its pipeline of targeted treatments and potential partnerships with larger pharmaceutical firms.
Congressional Interest in 35950 (NQI)
1 member of Congress has disclosed 1 trade in 35950 (NQI), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading NQI?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-12-22 | MICHAEL T. MCCAUL | sell | $1K-$15K |